Comerica Securities’s Harmony Biosciences HRMY Stock Holding History

Comerica Securities’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-89	Closed	-$4.9K	–	885
2022 Q4	$4.9K	Buy	+89	New	+$4.89K	﹤0.01%	1119

Other funds holding HRMY

Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Comerica Securities's HRMY Position: Q1 2023 in Review

Comerica Securities sold out of Harmony Biosciences (HRMY) in Q1 2023, closing a stake of 89 shares — an estimated $4.9K sold.

Comerica Securities first reported a position in HRMY in Q4 2022 and held it in 1 quarter. The position peaked at $4.9K in Q4 2022. 217 funds tracked by Wall St. Rank hold HRMY as of Q1 2023.

Comerica Securities reported no remaining Harmony Biosciences position as of Q1 2023 after selling out during the quarter.
Comerica Securities sold 89 Harmony Biosciences shares in Q1 2023, an estimated $4.9K.
Comerica Securities first reported a position in Harmony Biosciences in Q4 2022 and held it in 1 quarter.
Comerica Securities's Harmony Biosciences position peaked at $4.9K in Q4 2022.
217 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2023.

Based on Comerica Securities's 13F filing for Q1 2023, filed 27 Apr 2023.